- Oral presentation
- Open Access
New therapeutic approaches to HGPS based on progerin inhibition
Orphanet Journal of Rare Diseases volume 10, Article number: O8 (2015)
Hutchinson-Gilford Progeria Syndrome (HGPS) is caused by a de novo heterozygous mutation on LMNA gene that leads to accumulation of progerin, a mutant form of prelamin A. HGPS skin fibroblasts are characterized by multiple nuclear defects: nuclear shape abnormalities chromatin structure alterations, increased DNA damage and cell cycle alterations.
Retinoic acid may modulate LMNA gene transcription, due to the presence of a retinoic acid responsive element (L-RARE) in the LMNA promoter. Based on this knowledge, we investigated if all trans retinoic acid (ATRA) could lower progerin levels in HGPS fibroblasts. We also evaluated the effects of a combined treatment with rapamycin, a drug known to promote autophagy and reduce both farnesylated prelamin A and progerin amount.
We demonstrate a surprising effect of ATRA to repress Lamin A/C gene transcription and we show that the combined treatment with ATRA and rapamycin has a synergistic effect: it dramatically lowers progerin levels, restores both heterochromatin organization and nuclear shape, reduces DNA damage markers and improves cell viability. These promising results could open the way to a new therapeutic approach for HGPS.
About this article
Cite this article
Pellegrini, C. New therapeutic approaches to HGPS based on progerin inhibition. Orphanet J Rare Dis 10, O8 (2015). https://doi.org/10.1186/1750-1172-10-S2-O8
- Retinoic Acid
- Nuclear Shape
- Damage Marker
- Surprising Effect
- Shape Abnormality